CA2670830A1 - Methods of promoting cardiac repair using growth factors fused to heparin binding sequences - Google Patents
Methods of promoting cardiac repair using growth factors fused to heparin binding sequences Download PDFInfo
- Publication number
- CA2670830A1 CA2670830A1 CA002670830A CA2670830A CA2670830A1 CA 2670830 A1 CA2670830 A1 CA 2670830A1 CA 002670830 A CA002670830 A CA 002670830A CA 2670830 A CA2670830 A CA 2670830A CA 2670830 A1 CA2670830 A1 CA 2670830A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- igf
- fusion protein
- compound
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85840606P | 2006-11-13 | 2006-11-13 | |
| US60/858,406 | 2006-11-13 | ||
| US11/979,708 | 2007-11-07 | ||
| US11/979,708 US9187517B2 (en) | 2006-11-13 | 2007-11-07 | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
| PCT/US2007/023527 WO2008063424A2 (en) | 2006-11-13 | 2007-11-08 | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2670830A1 true CA2670830A1 (en) | 2008-05-29 |
Family
ID=39430287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002670830A Abandoned CA2670830A1 (en) | 2006-11-13 | 2007-11-08 | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9187517B2 (enExample) |
| EP (1) | EP2091550B1 (enExample) |
| JP (1) | JP2010508845A (enExample) |
| KR (1) | KR20090087061A (enExample) |
| AU (1) | AU2007322217A1 (enExample) |
| BR (1) | BRPI0718679A2 (enExample) |
| CA (1) | CA2670830A1 (enExample) |
| IL (1) | IL198708A0 (enExample) |
| MX (1) | MX2009005090A (enExample) |
| NO (1) | NO20092261L (enExample) |
| NZ (1) | NZ577235A (enExample) |
| RU (1) | RU2009122456A (enExample) |
| WO (1) | WO2008063424A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187517B2 (en) * | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
| ES2674567T3 (es) | 2010-05-21 | 2018-07-02 | Merrimack Pharmaceuticals, Inc. | Proteínas de fusión biespecíficas |
| JP2012093290A (ja) * | 2010-10-28 | 2012-05-17 | Sumitomo Bakelite Co Ltd | 医療用粒子および生理活性物質の捕捉方法 |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| US9637531B2 (en) | 2012-06-25 | 2017-05-02 | The Brigham And Women's Hospital, Inc | Selective cartilage therapy |
| WO2014004465A1 (en) * | 2012-06-25 | 2014-01-03 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| EP3355907B1 (en) | 2015-10-02 | 2021-01-20 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
| EA037848B1 (ru) * | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты) |
| JP2021516966A (ja) | 2018-03-09 | 2021-07-15 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組織への生物学的薬物の送達 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670483A (en) | 1992-12-28 | 1997-09-23 | Massachusetts Insititute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| US6037329A (en) | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
| US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
| CA2261292C (en) * | 1996-07-25 | 2008-09-30 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
| AUPP298498A0 (en) * | 1998-04-17 | 1998-05-07 | Gropep Pty Ltd | Matrix binding factor |
| AU2001288392A1 (en) * | 2000-08-30 | 2002-03-13 | University Of Delaware | Delivery system for heparin-binding growth factors |
| US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
| CA2496732A1 (en) | 2002-08-20 | 2004-03-04 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
| US7166574B2 (en) | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
| WO2005014619A2 (en) | 2003-03-28 | 2005-02-17 | Thomas Jefferson University | Heparin-binding peptides and uses thereof |
| US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| US7399831B2 (en) | 2004-10-25 | 2008-07-15 | The Brigham And Women's Hospital, Inc. | Targeted delivery of biological factors using self-assembling peptide nanofibers |
| US7429567B2 (en) | 2005-01-04 | 2008-09-30 | The Brigham And Women's Hospital, Inc. | Sustained delivery of PDGF using self-assembling peptide nanofibers |
| US9187517B2 (en) * | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
-
2007
- 2007-11-07 US US11/979,708 patent/US9187517B2/en active Active
- 2007-11-08 AU AU2007322217A patent/AU2007322217A1/en not_active Abandoned
- 2007-11-08 KR KR1020097012163A patent/KR20090087061A/ko not_active Withdrawn
- 2007-11-08 WO PCT/US2007/023527 patent/WO2008063424A2/en not_active Ceased
- 2007-11-08 CA CA002670830A patent/CA2670830A1/en not_active Abandoned
- 2007-11-08 NZ NZ577235A patent/NZ577235A/en not_active IP Right Cessation
- 2007-11-08 MX MX2009005090A patent/MX2009005090A/es active IP Right Grant
- 2007-11-08 EP EP07867389A patent/EP2091550B1/en active Active
- 2007-11-08 RU RU2009122456/15A patent/RU2009122456A/ru not_active Application Discontinuation
- 2007-11-08 BR BRPI0718679-7A2A patent/BRPI0718679A2/pt not_active IP Right Cessation
- 2007-11-08 JP JP2009536294A patent/JP2010508845A/ja active Pending
-
2009
- 2009-05-12 IL IL198708A patent/IL198708A0/en unknown
- 2009-06-12 NO NO20092261A patent/NO20092261L/no not_active Application Discontinuation
-
2015
- 2015-10-07 US US14/877,474 patent/US9969788B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090087061A (ko) | 2009-08-14 |
| EP2091550A2 (en) | 2009-08-26 |
| WO2008063424A3 (en) | 2008-09-12 |
| US9187517B2 (en) | 2015-11-17 |
| RU2009122456A (ru) | 2010-12-20 |
| IL198708A0 (en) | 2011-08-01 |
| US9969788B2 (en) | 2018-05-15 |
| EP2091550A4 (en) | 2009-12-09 |
| US20080138323A1 (en) | 2008-06-12 |
| AU2007322217A1 (en) | 2008-05-29 |
| US20160024170A1 (en) | 2016-01-28 |
| EP2091550B1 (en) | 2013-01-02 |
| WO2008063424A2 (en) | 2008-05-29 |
| JP2010508845A (ja) | 2010-03-25 |
| NZ577235A (en) | 2011-12-22 |
| MX2009005090A (es) | 2009-07-24 |
| NO20092261L (no) | 2009-08-06 |
| BRPI0718679A2 (pt) | 2014-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9969788B2 (en) | Methods of treating damaged cartilage tissue using growth factors fused to heparin binding sequences | |
| JP7693290B2 (ja) | Larファミリーホスファターゼの活性を阻害する組成物及び方法 | |
| JP2010508845A5 (enExample) | ||
| McLane et al. | Disintegrins in health and disease | |
| Swope et al. | Bombesin stimulates insulin secretion by a pancreatic islet cell line. | |
| Tokunou et al. | Engineering insulin-like growth factor-1 for local delivery | |
| CN116333094A (zh) | 一种重组人源化I型胶原蛋白α1及表达载体和应用 | |
| Garcia et al. | An evolutionarily conserved enzyme degrades transforming growth factor-alpha as well as insulin. | |
| CA2821715A1 (en) | Chimeric fibronectin matrix mimetics and uses thereof | |
| US20220289804A1 (en) | Bioactive agents and methods related thereto | |
| CN103694340B (zh) | 重组蛋白igf1-24及其应用 | |
| US20090269848A1 (en) | Technique for culture of mesenchymal stem cell utilizing laminin-5 | |
| Sara et al. | The biosynthesis of somatomedins and their role in the fetus | |
| CN101547704A (zh) | 使用融合至肝素结合序列的生长因子促进心脏修复的方法 | |
| KR102638021B1 (ko) | 섬유질환 예방 또는 치료용 재조합 융합 단백질 | |
| EP3702365A2 (en) | Modified egf protein, production method therefor, and use thereof | |
| Tsao et al. | Muscle derived stem cells stimulate muscle myofiber repair and counteract fat infiltration in a diabetic mouse model of critical limb ischemia | |
| CN101291955A (zh) | 具有组织再生功能的未活化多肽及其制备方法 | |
| SHIU et al. | Characterization of insulin-like growth factor II peptides secreted by explants of neonatal brain and of adult pituitary from rats | |
| Patruno et al. | Tat-MyoD fused proteins, together with C2c12 conditioned medium, are able to induce equine adult mesenchimal stem cells towards the myogenic fate | |
| AU2003287289B2 (en) | Promotion of peroxisomal catalase function in cells | |
| JPH07126181A (ja) | 骨折の予防および治療剤 | |
| US20110092427A1 (en) | Polypeptide and pharmaceutical composition containing the polypeptide | |
| KR102877150B1 (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
| Hazen‐Martin et al. | Electron microscopic immunostaining of nerve growth factor: Secretagogue stimulated submandibular glands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20131108 |